MedTrace Logo

A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria

NCT01847092 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 154

Last updated 2020-05-27

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if the study drug is safe, tolerable and active in reducing albuminuria in patients with Chronic Kidney Disease with Type 2 Diabetes.

Conditions

Interventions

DRUG

AZD1722

DRUG

Placebo

Placebo for AZD1722

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Ardelyx

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2015-03-31
Completion
2015-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01847092 on ClinicalTrials.gov